Computerized assessments and electroencephalography both hold promise for diagnosis and drug testing in Alzheimer’s disease, but the Food and Drug Administration does not yet know how to oversee the technology.
A new registry will match healthy volunteers with Alzheimer’s clinical trials based on ApoE genotype.
NIH announced a five-year study of Alzheimer’s biomarkers in middle-aged people with Down’s syndrome.
Scientists find that aggregates of different types of protein hinder the flow of nucleocytoplasmic transport, suggesting a common mechanism for neurodegeneration.
The BRCA1 protein protects neurons from DNA damage, but levels tumble in Alzheimer’s disease.
Mouse lines made by two different labs replicate the molecular pathology, but not the neurodegeneration, of ALS and FTD based on C9ORF72 expansions.
In various animal models of traumatic brain injury, acute treatments quiet inflammation and preserve neurons and their myelin sheaths.
Altered responses to visual stimuli could signify the extent of TDP-43 pathology in the brain, researchers predict.
Researchers at this year’s SfN meeting detailed different strategies and outcomes of passive and active vaccines.
The leaders of two large European trials report that promoting cardiac health, exercise, and mental activity helped maintained cognition in older adults.
Forget transgenics for a moment. Large collections of inbred and outbred mice could be an untapped treasure trove for Alzheimer’s researchers.
At CTAD, investigational Phase 1 drugs include a repackaged and a new anti-amyloid, a tau vaccine, and a repurposed cancer drug.
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.
Several therapeutic approaches in Phase 3 reported updates at the CTAD conference earlier this month in Barcelona. Read about levetiracetam, deep brain stimulation, and scyllo-inositol.
The CTAD conference featured discussion among many scientists of how to measure a drug’s effect in pre-dementia patients who are so mildly impaired that established tools have trouble picking up improvement. Better cognitive tools are needed.